Trial of Brain Computer Interface as ALS Speech Aid Being Planned
The Wyss Center for Bio and Neuroengineering is planning to launch a trial of its wireless brain computer interface (BCI),…
Articles by Marta Figueiredo, PhD
Treg Therapy Found Safe, Effective at Slowing ALS in Small Trial
Treating patients with their own immune regulatory T-cells (Tregs), in combination with IL-2 — a protein that boosts the…
Cholesterol Transporter May Be Strongest Trigger of Sporadic ALS
The cerebrospinal fluid of people with sporadic amyotrophic lateral sclerosis (sALS), but not of those with familial forms…
Masitinib Again Under Review in EU as Potential ALS Treatment
The European Medicines Agency (EMA) has agreed to review an application seeking the conditional approval of AB Science’s masitinib,…
Trial of Brain Computer Interface Still Recruiting ALS Patients, Others
A clinical trial is evaluating whether a new, implantable brain computer interface (BCI) is able to decode brain signals —…
BrainStorm Plans to File for NurOwn Approval in US for ALS
Brainstorm Cell Therapeutics is preparing to file an application with the U.S. Food and Drug Administration (FDA) requesting approval of…
AMX0035, Radicava ORS Costs Could Cloud Therapies’ Benefits: ICER
Note: This story was updated Aug. 10, 2022, to clarify the U.S. Food and Drug Administration advisory committee voted…
NeuroSense Joins EverythingALS to Advance ALS Treatments
NeuroSense Therapeutics has joined EverythingALS’s open innovation consortium to accelerate the development of treatments for amyotrophic lateral sclerosis (ALS). NeuroSense…
Albrioza, Oral ALS Therapy Known as AMX0035, Available in Canada
Albrioza, an oral therapy for amyotrophic lateral sclerosis (ALS) still widely known as AMX0035, is now commercially available in Canada,…
1st Patient Dosed in Basket Trial of ALS Therapy Candidate SLS-005
The first patient has been dosed in an open-label Phase 2 trial that’s evaluating Seelos Therapeutics’ experimental therapy SLS-005…